Edition:
United Kingdom

Audentes Therapeutics Inc (BOLD.OQ)

BOLD.OQ on NASDAQ Stock Exchange Global Market

33.40USD
15 Aug 2018
Change (% chg)

$0.02 (+0.06%)
Prev Close
$33.38
Open
$32.82
Day's High
$33.85
Day's Low
$31.72
Volume
106,445
Avg. Vol
126,645
52-wk High
$46.12
52-wk Low
$17.67

Chart for

About

Audentes Therapeutics, Inc. is an early-stage biotechnology company. The Company is focused on developing and commercializing gene therapy products for patients suffering from serious, life-threatening rare diseases caused by single gene defects. The Company has a portfolio of product candidates, including AT132 for the... (more)

Overall

Beta: --
Market Cap(Mil.): $722.67
Shares Outstanding(Mil.): 27.78
Dividend: --
Yield (%): --

Financials

  BOLD.OQ Industry Sector
P/E (TTM): -- 85.68 32.76
EPS (TTM): -3.54 -- --
ROI: -57.99 1.78 14.61
ROE: -145.70 3.28 16.33

BRIEF-Audentes Announces Data From First Dose Cohort Of ASPIRO

* AUDENTES ANNOUNCES CONTINUING POSITIVE DATA FROM FIRST DOSE COHORT OF ASPIRO, A PHASE 1/2 CLINICAL TRIAL OF AT132 IN PATIENTS WITH X-LINKED MYOTUBULAR MYOPATHY

16 May 2018

BRIEF-Audentes Therapeutics Reports Qtrly Loss Per Share $0.74

* AUDENTES THERAPEUTICS REPORTS FIRST QUARTER 2018 FINANCIAL RESULTS AND PROVIDES CORPORATE UPDATE

09 May 2018

BRIEF-Audentes Therapeutics CEO Matthew Patterson's 2017 Total Compensation Was $6.9 Million

* AUDENTES THERAPEUTICS INC SAYS CEO MATTHEW PATTERSON'S 2017 TOTAL COMPENSATION WAS $6.9 MILLION – SEC FILING Source text for Eikon: (http://bit.ly/2KknZ9F) Further company coverage:

27 Apr 2018

BRIEF-Audentes Therapeutics Q4 Loss Per Share ‍$0.82

* AUDENTES THERAPEUTICS REPORTS FOURTH QUARTER 2017 AND FULL YEAR FINANCIAL RESULTS AND PROVIDES CORPORATE UPDATE

08 Mar 2018

Competitors

  Price Chg
Amicus Therapeutics, Inc. (FOLD.OQ) $13.39 -0.53
Sanofi SA (SASY.PA) €72.16 --

Earnings vs. Estimates